IntegraGen becomes First Certified French Service Provider for Illumina GoldenGate and Infinium Genotyping

Concurrent with the annual European Human Genetics Conference in Nice, France, Illumina, Inc. announced today that IntegraGen SA, a personalized healthcare company focused on the development and commercialization of molecular diagnostic tests for complex diseases and provider of genetic services, has received Illumina Certified Service Provider (CSPro™) certification for GoldenGate^® and Infinium^® genotyping technologies.

Illumina, a San Diego-based company, is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the analysis of genetic variation and biological function. The GoldenGate assay is Illumina’s first array-based platform that combines high-sample throughput, high multiplexing, and single-site CpG resolution for DNA methylation profiling. The Infinium Whole-Genome Genotyping BeadArray™ solution offers single or multi-sample BeadChip formats and high-density architecture with the flexibility to add additional custom SNP Assays.

“IntegraGen is a company dedicated to offering high-quality services to other research institutes, either private or academic, and is the first laboratory in France to achieve CSPro certification for GoldenGate and Infinium Genotyping,” said Karen Possemato, Illumina’s Director of Corporate Marketing commented. “By becoming a member of CSPro, they have further demonstrated their commitment to the life science community, providing delivery of the highest-quality data available for genetic analysis applications.”

Emmanuel Martin, IntegraGen’s Director of Services and Arrays said: “IntegraGen is proud of its ability to leverage core competencies and provide genetic services to the research community. Receiving Illumina CSPro certification is an endorsement of both Illumina and IntegraGen’s commitment to quality, and provides our customers with even greater confidence in our ability meet their needs.”

As a customer of IntegraGen, Jessica Zucman-Rossi, M.D., Ph.D., has been using Illumina technology in a pilot study for loss of heterozygosity (LOH) analysis in liver tumors at the Human Polymorphism Study Center (CEPH) in Paris. “We also chose Illumina technology to test for promoter methylation in liver tumors because there were a large number of genes available for testing with this system, and the ability to quantify methylation levels is a real advantage. My team was able to analyze a large number of samples in each experiment, and the time taken to generate results was short, generating a large amount of data.” She added, “The results we attained were excellent, achieving methylation profiling of 96 tumor samples on more than 1,500 CpG. The data are robust, and we are currently preparing a second series of samples.”